AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Close
Create a link to this page
Copy and paste this link tag into your Web page or blog:
<a href="http://www.accessmylibrary.com/coms2/summary_0286-6940101_ITM" title="Facts and information about Upping the anti. (goodnews).(antioxidants)(Brief Article)">Upping the anti. (goodnews).(antioxidants)(Brief Article)</a>
Close
Set up an RSS feed that alerts you when new articles from Better Nutrition are available.
Frequently asked questions about RSS feeds
Upping the anti. (goodnews).(antioxidants)(Brief Article)
Certain antioxidants may protect against prostate cancer and rheumatoid arthritis, according to two new studies.
Researchers from the Johns Hopkins Bloomberg School of Public Health in Baltimore studied the relationship between antioxidants and prostate cancer.
Another team of researchers at the Mayo Clinic in Rochester, Minnesota, reviewed the protective effects of antioxidants against rheumatoid arthritis.
The Maryland researchers learned that while lycopene did not seem to have a protective effect against prostate cancer, the gamma-tocopherol isomer of vitamin E did.
Isomers are effectively identical compounds ...
Related articles from newspapers, magazines, journals, and more
For more facts and information, see all results
- Biotechs Well Ahead of Big Pharma in The Development of Map Kinase-Based...
- Press release article from: PR Newswire April 23, 2003 700+ words
...MAP kinase- based therapeutics have blockbuster potential in the rheumatoid arthritis, Crohn's disease, ischemic stroke, Parkinson's disease, and prostate cancer drug markets. "The recent acquisition of Scios by Johnson &...
- The Immune Response Corporation Announces Results From Phase II Clinical Trials...
- Press release article from: PR Newswire January 7, 1997 700+ words
...based therapy for rheumatoid arthritis. The treatment for rheumatoid arthritis demonstrated safety...HIV, psoriasis, rheumatoid arthritis, multiple sclerosis...preclinical studies for prostate cancer. The company is...
- The Immune Response Corporation Treats First Patient in Phase IIb Clinical...
- Press release article from: PR Newswire December 2, 1997 700+ words
...its Phase IIb rheumatoid arthritis clinical trial...suffer from rheumatoid arthritis and that they...therapies for HIV, rheumatoid arthritis, psoriasis...preclinical studies for prostate cancer. The company...
- The Immune Response Corporation Presents Results from Phase II Clinical Trial...
- Press release article from: PR Newswire November 11, 1997 700+ words
...controlled, rheumatoid arthritis trial was designed...approaches to treat rheumatoid arthritis," said Dr...therapies for HIV, rheumatoid arthritis, psoriasis...preclinical studies for prostate cancer. The company...
- Hollis-Eden Pharmaceuticals Announces Filing of IND with APOPTONE(TM) in...
- Press release article from: Business Wire February 19, 2008 700+ words
...clinical trial of APOPTONE in prostate cancer patients during the second...initiate our clinical trial in prostate cancer," said Richard B. Hollis...ulcerative colitis, prostate cancer, and rheumatoid arthritis, are major market opportunities...
- MedImmune Initiates Two Phase 2 Clinical Trials for Vitaxin(R); - Melanoma and...
- Press release article from: PR Newswire September 9, 2003 700+ words
...patients with rheumatoid arthritis (RA). "As...2 studies in prostate cancer and psoriasis...precipitously. Phase 2 Rheumatoid Arthritis Trial MedImmune...treatment extension. Rheumatoid arthritis is a chronic...
- MedImmune Discontinues Rheumatoid Arthritis and Psoriasis Trials for Vitaxin(R).
- Press release article from: PR Newswire August 30, 2004 700+ words
...terminate Phase 2 testing of Vitaxin(R) in patients with rheumatoid arthritis (RA) and psoriasis based on preliminary data suggesting...Vitaxin continues to advance with studies in melanoma and prostate cancer. About Vitaxin Vitaxin targets the alpha-v beta-3...
- MedImmune discontinues rheumatoid arthritis and psoriasis trials for Vitaxin.
- News wire article from: Asia Africa Intelligence Wire August 30, 2004 700+ words
...terminate Phase II testing of Vitaxin in patients with rheumatoid arthritis (RA) and psoriasis based on preliminary data suggesting...Vitaxin continues to advance with studies in melanoma and prostate cancer. Vitaxin targets the alpha-v beta-3 integrin, which...
- RhuDex Enters Clinical Phase IIa Trial in Rheumatoid Arthritis.
- News wire article from: Europe Intelligence Wire January 23, 2007 700+ words
...novel, orally available substance for the treatment of rheumatoid arthritis, originating from Active Biotech's patented CD80 antagonists...comprise the three orally administered compounds TASQ for prostate cancer 57-57 for SLE and RhuDex for RA. In addition, the...
- Event Brief of Isis Pharmaceuticals Conference Call to Discuss the Results of a...
- News wire article from: The America's Intelligence Wire January 5, 2004 700+ words
...partner OncoGenex will be reporting interesting data on target reduction of cluster in prostate cancer. And Phase I, Phase II, in patients with prostate cancer this year. Our partner ATL will report Phase I data of our VLA-4 antagonus [phonetic...
